Participants
“Having attended for the first time, we quickly realized how valuable the Biopharma Sustainability Roundtable was. We found it highly relevant, with discussions that provided valuable information on topics we are working on right now. The open exchange with our peers helped us to better understand opportunities and challenges in pursuing our sustainability work.”
Biopharma Participation
Biopharma Sustainability Roundtable participation includes a wide range of companies, represented by senior level executives with strategic and operational responsibility for Sustainability, Corporate Responsibility, or ESG.
Past Participants
(acquired by AstraZeneca)
(acquired by BMS)
(acquired by AstraZeneca)
(Part of Merck KGaA)
(acquired by Takeda)
Investor Network Participants
Guests and Collaborators
- Access Accelerated
- Access to Medicines Foundation
- BIO
- Bill & Melinda Gates Foundation
- BU School of Public Health
- British Standards Institute
- BSR Healthcare Working Group
- Capitals Coalition
- CARB-X
- CDP
- CECP’s CEO Investor Forum
- DuPont
- ECOFACT
- EFPIA
- EFRAG
- Future-Fit Foundation
- GBI
- GE Healthcare
- Gibson Dunn
- GRI
- Harvard Business School
- Health Outcomes Observatory, H2O
- High Meadows Institute
- IFPMA
- Impact Management Project
- Impact-Weighted Accounts Project, Harvard Business School
- International Integrated Reporting Council
- ISSB/IFRS Foundation
- ISS ESG (oekom)
- MIT Sloan Sustainability Initiative
- MSCI
- NASDAQ CPH
- Oxford University Saïd Business School
- Paxus LLP
- PSCI
- Polecat
- Purple Strategies
- Quantis
- RepRisk
- Rockefeller Foundation
- SASB
- S&P Global
- Thermofisher
- TNFD
- Sustainable Medicines Partnership
- SustainAbility (ERM)
- Sustainalyltics
- Swiss Re
- UN Global Compact
- US Green Building Council
- Value Balancing Alliance
- Value Reporting Initiative
- WBCSD
- WifOR
- World Economic Forum
- Wharton Business School
- YewMaker